Effect of denosumab on fasting glucose in women with diabetes or prediabetes from the FREEDOM trial.

Nicola NapoliNicola PannacciulliEric VittinghoffDaria CrittendenJang YunAndrea WangRachel WagmanAnn V Schwartz

Published in: Diabetes/metabolism research and reviews (2018)

DMAb did not affect FSG in postmenopausal osteoporotic women with prediabetes or diabetes. There was evidence of modest FSG lowering with DMAb in those with diabetes who were not on ADM. It remains to be determined whether blockade of RANKL has a clinically important effect on glucose metabolism.

Keyphrases

type diabetes
glycemic control
cardiovascular disease
bone mineral density
blood glucose
study protocol
clinical trial
postmenopausal women
insulin resistance
randomized controlled trial
metabolic syndrome